Cognitive impairment and dementia in basal ganglia disorders

Current Neurology and Neuroscience Reports

Volumn 5, Issue 5, 2005, Pages 355-363

  Stout, Julie C ^a   Johnson, Shannon A ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MINOCYCLINE; PERGOLIDE; RIVASTIGMINE;

BRAIN DEPTH STIMULATION; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG TOLERABILITY; EXPERIMENTAL DESIGN; EXTRAPYRAMIDAL SYNDROME; FUNCTIONAL DISEASE; HUMAN; HUNTINGTON CHOREA; LEWY BODY; MEDICAL LITERATURE; PARKINSON DISEASE; PHENOTYPE; PROGRESSIVE SUPRANUCLEAR PALSY; PSYCHOLOGIC ASSESSMENT; REVIEW;

EID: 26444472441     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-005-0059-3     Document Type: Review

References (50)

1. Aylward EH, Sparks BF, Field KM, et al.: Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004, 63:66-72.
2. Hennenlotter A, Schroeder U, Erhard P, et al.: Neural correlates associated with impaired disgust processing in pre-symptomatic Huntington's disease. Brain: J Neurol 2004, 127:1446-1453.
3. Kim J, Reading SAJ, Brashers-Krug T, et al.: Functional MRI study of a serial reaction time task in Huntington's disease. Psychiatry Res: Neuroimaging 2004, 131:23-30.
4. Paulsen JS, Zimbelman JL, Hinton SC, et al.: fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's disease. Am J Neuroradiol 2004, 25:1715-1721.
5. Reading SA, Dziorny AC, Peroutka LA, et al.: Functional brain changes in presymptomatic Huntington's disease. Ann Neurol 2004, 55:879-883.
6. Blekher TM, Yee RD, Kirkwood SC, et al.: Oculomotor control in asymptomatic and recently diagnosed individuals with the genetic marker for Huntington's disease. Vision Res 2004, 44:2729.
7. Kassubek J, Juengling FD, Kioschies T, et al.: Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 2004, 75:213.
8. Campbell MC, Stout JC, Finn PR: Reduced autonomic responsiveness to gambling task losses in Huntington's disease. J Int Neuropsychol Soc 2004, 10:239-245.
9. Soliveri P, Monza D, Paridi D, et al.: Neuropsychological follow up in patients with Parkinson's disease striatonigral degeneration-type multisystem atrophy and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2000, 69:313-318.
10. Grafman J, Litvan I, Stark M: Neuropsychological features of progressive supranuclear palsy. Brain Cognition 1995, 28:311-320.
11. Nath U, Ben-Shlomo Y, Thomson RG, et al.: Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology 2003, 25:910-916.
12. Brenneis C, Seppi K, Schocke M, et al.: Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 2004, 75:246-249.
13. Williams DR, de Silva R, Paviour DC, et al.: Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005, 128:1247-1258.
14. McKeith IG, Galasko D, Kosaka K, et al.: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium of DLB international workshop. Neurology 1996, 47:1113-1124.
15. Press DZ: Parkinson's disease dementia. N Engl J Med. 2004, 351:2547-2549.
16. Litvan I, Bhatia KP, Burn DJ, et al.: Movement Disorders Society Scientific Issue Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003, 18:467-486.
17. Folytynie T, Brayne CE, Robbins TW, Barker RA: The cognitive ability of an incident cohort of Parkinson's patients in the U.K. The CamPaIGN study. Brain 2004, 127:550-560.
18. Levin BE, Katzen HL: Early cognitive changes and nondementing behavioural abnormalities in Parkinson's disease. In Advances in Neurology: Behavioral Neurology of Movement Disorders. Edited by Weiner WJ, Lange AE. New York: Raven Press; 1995:85-95.
19. Monchi O, Petrides M, Doyon J, et al.: Neural bases of set shifting deficits in Parkinson's disease. J Neurosci 2004, 24:702.
20. Nagano-Saito A, Kato T, Arahata Y, et al.: Cognitive and motor related regions in Parkinson's disease: FDOPA and FDG PET studies. NeuroImage 2004, 22:553.
21. Weintraub D, Moberg PJ, Culbertson WC, et al.: Evidence for impaired encoding and retrieval memory profiles in Parkinson disease. Cogn Behav Neurol 2004, 17:195-200.
22. Wylie SA, Stout JC: Enhanced negative priming in Parkinson's disease. Neuropsychology 2002, 16:242-250.
23. Wylie SA, Stout JC, Bashore TR: Activation of conflicting responses in Parkinson's disease: evidence for degrading and facilitating effects on response time. Neuropsychologia 2005, 43:1033-1043.
24. Dujardin K, Defebvre L, Duhamel A, et al.: Cognitive and SPECT characteristics predict progression of Parkinson's disease in newly diagnosed patients. J Neurol 2004, 251:1383.
25. Gilman S, Koeppe RA, Little R, et al.: Differentiation of Alzheimer's disease from dementia with lewy bodies utilizing positron emission tomography with [18F] fluorodeoxyglucose and neuropsychological testing. Exp Neurol 2005, 191:S95-SIO3.
26. Hamilton JM, Salmon DP, Galasko D, et al.: A comparison of episodic memory deficits in neuropathologically-confirmed Dementia with Lewy bodies and Alzheimer's disease. J Int Neuropsychol Soc 2004, 10:689-697.
27. Kraybill ML, Larson EB, Tsuang DW, et al.: Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 2005, 64:2069-2073.
28. Tam CW, Burton EJ, McKeith IG, et al.: Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with lewy bodies.. Neurology 2005, 64:861-865.
29. Cormack E Aarsland D, Ballard C, Tovee MJ: Pentagon drawing and neuropsychological performance in dementia with Lewy bodies, Alzheimers disease, Parkinson's disease, and Parkinson's disease with dementia. Int J Geriatr Psychiatry 2004, 19:371.
30. Ralph MA, Powell J, Howard D, et al.: Semantic memory is impaired in both dementia with lewy bodies and dementia of Alzheimer's type: a comparative neuropsychological study and literature review. J Neurol Neurosurg Psychiatry 2001, 70:149-156.
31. Olichney JM, Galasko D, Salmon DP, et al.: Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 1998, 51:351-357.
32. Aarsland D, Andersen K, Larsen JP, et al.: The rate of cognitive decline in Parkinson disease. Arch Neurol 2004, 61:1906-1911.
33. Popescu A, Lippa CF: Parkinsonian syndromes: Parkinson's disease dementia, dementia with lewy bodies, and progressive supranuclear palsy. Clin Neurosci Res 2004, 3:461.
34. Zgaljardic DL, Foldi NS, Borod JC: Cognitive and behavioral dysfunction in Parkinson's disease: neurochemical and clinicopathological contributions. J Neural Transmission 2004, 111:1287.
35. Morrison CE, Borod JC, Perrine K, et al.: Neuropsychological functioning following bilateral subthalamic nucleus stimulation in Parkinson's disease. Arch Clin Neuropsychol 2004, 19:165.
36. Simard M, van Reekum R: The acetylcholinesterase inhibitors for treatment of cognitive and behavioral symptoms in dementia with lewy bodies. J Neuropsychiatry Clin Neurosci 2004, 16:409-425.
37. Thomas M, Ashizawa T, Jankovic J: Minocycline in Huntington's disease: a pilot study. Mov Disord 2004, 19:692-695.
38. Nehl C, Paulsen JS, and the Predict-HD HSG Investigators: Cognitive and psychiatric aspects of Huntington's disease contribute to functional capacity. J Nervous Mental Dis 2004, 192:72-74.
39. Weintraub D, Moberg PJ, Duda JE, et al.: Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 2004, 52:784.z
40. Radford KA, Lincoln NB, Lennox G: The effects of cognitive abilities on driving in people with Parkinson's disease. Disabil Rehabil 2004, 26:65.
41. Witt K, Pulkowski U, Herzog J. et al.: Deep brain stimulation of the subthalamic nucleus improves cognitive flexibility but impairs response inhibition in Parkinson disease. Arch Neurol 2004, 61:697-700.
42. Funkiewiez A, Ardouin C, Caputo E, et al.: Long term effects of bilateral subthalamic nucleus stimulation on cognitive function mood and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004, 75:834.
43. Dujardin K, Blairy S, Defebvre L, et al.: Subthalamic nucleus stimulation induces deficits in decoding emotional facial expressions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004, 75:202.
44. Brusa L, Tiraboschi P, Koch G, et al.: Pergolide effect on cognitive functions in early-mild Parkinson's disease. J Neural Transmission 2005, 112:231.
45. Morrison CE, Borod JC, Brin MF. et al.: Effects of levodopa on cognitive functioning in moderate to severe Parkinson's disease (MSPD). J Neural Transmission 2004, 111:1333.
46. Fern-Pollak L, Whone AL, Brooks DJ, and Mehta MA: Cognitive and motor effects of dopaminergic medication withdrawal in Parkinson's disease. Neuropsychologia 2004, 42:1917.
47. Emre M, Aarsland D, Albanese A, et al.: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004, 351:2509.
48. Leroi I, Brandt J, Reich SG, et al.: Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkison's disease. Int J Geriatr Psychiatry 2004, 19:1.
49. Beversdorf DQ, Warner JL, Davis RA, et al.: Donepezil in the treatment of dementia with lewy bodies. Am J Geriatr Psychiatry 2004, 12:542-544.
50. Lemay S, Chouinard S, Blanchet P, et al.: Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Progress in Neuropsychopharmacology & Biological Psychiatry 2004, 28:31.